Results of the Extraordinary General Shareholders’ Meeting of December 16, 2020
17/12/2020 – AB Science provides the results of the Extraordinary Shareholders’ Meeting of December 16, 2020
Corrective press release regarding adverse events information from study AB09004
17/12/2020 – AB Science issues a corrective press release regarding adverse events information from study AB09004 reported on December 16, 2020
Live webcast on Thursday December 17, 2020 on masitinib’s results in Alzheimer’s Disease
16/12/2020 – AB Science will host a live webcast on December 17, 2020 on masitinib results in Alzheimer’s Disease
Positive Phase 2/3 study AB09004 with masitinib in Alzheimer’s Disease
16/12/2020 – AB Science announces that Phase 2B/3 study evaluating masitinib in Alzheimer’s disease met its primary endpoint
Live webcast on Friday December 11, 2020 on masitinib’s results in pancreatic cancer
08/12/2020 – AB Science will host a live webcast on December 11, 2020 with key opinion leaders to discuss recently reported results from the Phase 3 masitinib trial in pancreatic cancer
Positive confirmatory Phase 3 study AB12005 with masitinib in first line pancreatic cancer with pain
04/12/2020 – AB Science announces that confirmatory Phase 3 study AB12005 with masitinib in first line pancreatic cancer with pain met its primary objective to demonstrate increase in survival
Signature of a 15.0 million financing deal with the European Investment Bank
30/11/2020 – AB Science announces the signature of a 15.0 million financing deal with the European Investment Bank to support clinical development of masitinib in Covid-19
AB Science to present results from its AB07015 study in severe asthma at the annual European Respiratory Society International Congress
08/09/2020 – AB Science to present results from its Phase 3 AB07015 study in severe asthma at the annual European Respiratory Society International Congres
AB Science to present results from its AB07002 study in progressive forms of MS at MSVirtual2020
07/09/2020 – AB Science to present results from its Phase 2B/3 AB07002 study in progressive forms of multiple sclerosis at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting
New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in vitro
02/09/2020 – New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in-vitro and is a promising candidate for treating COVID-19